White Sandoz logo on blue background

Sandoz spin-off

Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.

Construction Kundl, Austria

Sandoz investing to increase production of much-needed antibiotics

Sandoz is pushing ahead with its capacity expansion program for much-needed antibiotic medicines. As shown in the photo, construction of a new USD 50m plant, announced in November 2022, is already well underway. Our Kundl site in Austria will also manufacture antibiotics for children (pediatric formulations). In total, the company is investing USD 250m to expand its antibiotic manufacturing capabilities in Europe. This has already led to a double-digit increase in capacity in 2022 and another double-digit increase is planned for 2023.


Products & Services

At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine.



We are a pioneer and a global leader in biosimilars with over a decade of experience.